Search Bar & Filters
Found 39 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of stereotactic radiotherapy SRT as a treatment strategy for patients with oligoprogressive metastatic renal cell carcinoma RCC who are already undergoing systemic therapies. This phase II study focuses on patients whose cancer has progressed in a limited number of sites despite ongoing treatment, aiming to control local tumors and delay the need for additional systemic therapies. The study builds on evidence that SRT can effectively target RCC metastases and may also stimulate the immune system when combined with immunotherapy. The study involves delivering high-dose stereotactic radiotherapy to metastatic sites showing progression in patients receiving systemic therapies such as targeted drugs or immunotherapy. Eligible patients have 1 to 3 progressing metastases in up to 2 organs, with lesions measuring 4 cm or less, and will continue their current systemic treatment while receiving SRT either concurrently or sequentially. This approach aims to locally control progressing tumors and potentially extend the effectiveness of ongoing therapy. Participants will undergo imaging assessments to confirm disease progression and measure tumor response, with follow-up visits to monitor tumor control and treatment side effects. Researchers will evaluate progression-free survival six months after randomization as the primary outcome, along with local and overall control rates and treatment-related adverse events. The study includes monitoring for safety and effectiveness up to 12 months post-treatment, with participants involvement lasting until at least one month after treatment completion.
Actively Recruiting
Researchers are evaluating the efficacy and safety of tulisokibart in people with moderately to severely active Crohns disease. This program includes two separate studies Study 1, which involves both induction and maintenance treatment phases, and Study 2, which includes only the induction treatment phase. The main goals are to see if one or more doses of tulisokibart are better than placebo in achieving clinical remission according to specific Crohns Disease Activity Index scores or stool frequency and abdominal pain scores, and to assess endoscopic response at weeks 12 and 52 depending on the study and regulatory region. Participants receive tulisokibart either intravenously or subcutaneously at different dose levels depending on the study arm. Some receive a high dose induction followed by high or low dose maintenance, others receive low dose throughout, and some receive placebo. Extension arms allow participants who complete their original treatment to continue receiving high or low dose subcutaneous tulisokibart if they qualify. The study uses random assignment to treatment groups and is double-blind, meaning neither participants nor researchers know who receives the drug or placebo. Throughout the studies, participants undergo evaluations at specified weeks to measure clinical remission, clinical response, endoscopic response, and other outcomes such as fatigue and quality of life. Safety is monitored by tracking adverse events and discontinuations due to side effects. The overall participation may last up to 52 weeks for Study 1 and 12 weeks for Study 2, with assessments at multiple points to carefully observe treatment effects and safety.
Actively Recruiting
This research aims to evaluate the impact of socio-aesthetic care on anxiety levels in cancer patients undergoing chemotherapy. The study focuses on patients receiving chemotherapy every 14 or 21 days for cancers such as lung, breast, digestive, colorectal, or gynecological types. The main purpose is to compare patients State Anxiety scores before treatment and after the third chemotherapy cycle. Participants will be divided into two groups one group will receive three sessions of socio-aesthetic care during their first chemotherapy administration, provided by a socio-esthetician. The other group will receive supportive care available at the center, including psychology consultations, sophrology, art therapy, physiotherapy, and hypnosis, but will not have socio-aesthetic care. Patients will be seen six times at inclusion, during the first four chemotherapy courses, and at the end of chemotherapy. During the study, patients will complete anxiety questionnaires to measure their anxiety levels at various points. Researchers will assess changes in the State Anxiety score from the start of treatment through the third chemotherapy cycle, which lasts up to 21 days per cycle. Safety and adherence will be monitored throughout the chemotherapy period, with the total participation duration covering the chemotherapy cycles and follow-up visits.
Actively Recruiting
Falls among older adults are a significant health concern, causing millions of incidents, thousands of deaths, and many hospitalizations each year. This study focuses on older adults living at home and aims to explore how adding a specific training module to balance workshops can help improve the ability to get up from the floor after a fall, a skill that is often overlooked despite its importance in preventing serious complications. Participants will join one of two groups one will receive standard balance workshops designed to improve balance, mobility, strength, and fall prevention the other will receive the same workshops with an added 20-minute module focused on safely learning to get up from the floor. This module includes exercises tailored to each participants ability, covering floor transitions and strategies to manage apprehension or physical limitations. Throughout the study, participants will be assessed on their ability to stand up from the floor, mobility, lower limb strength, balance, confidence in daily balance, self-efficacy for getting up, physical activity levels, and number of falls. These measurements will be taken before and after the program, with some assessed again 12 weeks later. The study will also evaluate how well the new module is implemented and accepted by participants and therapists over six months.
Actively Recruiting
This research aims to reduce extubation failure in critically ill patients with acute brain injuries who have impaired consciousness. These patients often require mechanical ventilation with tracheal intubation, and after their acute neurological condition is treated, doctors need to carefully wean them off ventilators to avoid complications like pneumonia. Current guidelines for ventilator weaning do not include brain-injured patients with impaired consciousness, so this study evaluates a simple clinical score to help decide when to safely remove the breathing tube. Participants will be assigned by random clusters of intensive care units to receive either usual care or care guided by the extubation readiness clinical score. After a successful spontaneous breathing trial, clinicians in the intervention group will use the score based on swallowing, gag reflex, cough, and consciousness level to decide on extubation. If the score is above 9, extubation should proceed. Those in the usual care group will follow standard ICU ventilator weaning protocols. The study uses a stepped wedge cluster randomized design. During the study, patients are assessed daily for readiness to breathe without the ventilator. Researchers will monitor extubation failure from the time of extubation up to five days later. They will also track other outcomes such as time to extubation, duration of mechanical ventilation, reintubation rates, pneumonia occurrence, hospital stay length, and neurological outcomes up to 90 days. This thorough evaluation helps understand how the score may improve the timing and success of extubation in this vulnerable group.
Actively Recruiting
Researchers are studying the use of ribociclib, a CDK46 inhibitor, in women with early hormone receptor-positive HR and HER2-negative breast cancer who are at intermediate risk of cancer recurrence. The study aims to see if patients can avoid chemotherapy, which has significant side effects, by using ribociclib along with hormone therapy after surgery. This phase III trial builds on the NATALEE study, which showed that ribociclib added to hormone therapy improved survival free of invasive disease in similar patients. Participants will be randomly assigned to one of two groups one receiving ribociclib plus endocrine hormone therapy, and the other receiving chemotherapy followed by ribociclib and endocrine therapy. Ribociclib treatment lasts for three years, and chemotherapy is given before starting ribociclib and hormone treatment. The trial aims to compare the outcomes of chemotherapy de-escalation versus standard treatment in this patient group. During the study, participants will attend scheduled visits for treatment and monitoring, including laboratory tests, heart monitoring with ECG, and questionnaires about their quality of life. Researchers will track invasive breast cancer-free survival and other outcomes such as overall survival and treatment side effects for up to 12 years. Safety and quality of life assessments will continue during and after treatment to evaluate the long-term effects and benefits of the treatment approaches.
Actively Recruiting
Researchers are evaluating the safety and performance of remote monitoring functions in ALIZEA, BOREA, and CELEA pacemakers for patients with bradycardia. This observational clinical investigation focuses on the devices Right Atrial Autothreshold RAAT, Right Ventricular Autothreshold RVAT, and remote alert features. The study aims to document these functions over time to better understand their reliability and safety. Participants will be included soon after pacemaker implantation and followed for 48 months. Follow-up visits occur both on-site and remotely at 1 to 3 months, 6 months, 12 months, 24 months, and 48 months after inclusion. During these visits, the remote monitoring functions and the pacing systems performance will be measured, and safety will be continuously monitored throughout the study. Throughout the study, researchers will assess cardiac pacing thresholds, technical remote alerts, and the usability of the pacemaker and remote monitoring systems. Evaluations include Right Atrial and Right Ventricular pacing thresholds at multiple timepoints up to 48 months. Participants will undergo scheduled check-ins involving measurements, monitoring, and safety assessments, with the total study duration lasting four years after enrollment.
Actively Recruiting
Researchers are evaluating a standardized process that combines expert review and advanced software to improve treatment planning for patients undergoing re-irradiation with curative intent. This study aims to determine how often this approach changes treatment plans by using a group of radiotherapists and physicists to validate re-irradiation indications and dose accumulations. The study addresses challenges in managing dose limits to organs at risk during repeat radiation treatments, aiming to reduce treatment inequalities across centers. The intervention involves a multidisciplinary and multicenter validation process where technical data from previous and planned irradiations are reviewed using deformable fusion software called MiM. This software sums doses in Equivalent Dose 2 Grays EQD2 to evaluate cumulative radiation exposure. Patients undergo initial opinion assessment, followed by collective expert reviews of imaging, dose plans, and dose summations in several steps. If re-irradiation is validated, patients proceed with treatment according to the validated plan. Participants are followed for up to two years after re-irradiation to monitor treatment tolerance and effectiveness through standard practice visits approximately every three months. Outcomes measured include the rate of treatment plan changes due to the intervention, local control rates at multiple time points up to 24 months, safety, and impacts on clinical practices. Dose summation timing and treatment adherence are also evaluated. The study enrollment is for adults aged 18 years and older who meet specific clinical criteria for curative re-irradiation.
Actively Recruiting
This research focuses on classifying genetic variants found in families with a history of hereditary cancer, especially breast and ovarian cancers. It aims to improve genetic counseling by studying the co-segregation of specific gene variants, including those in BRCA1, BRCA2, PALB2, and other genes tested in multigene panels. The study uses data from large French national databases to better understand the disease risk linked to these variants and to support clinical decision-making. Participants include index cases carrying variants of interest classified as class 3 variants of uncertain significance, class 4 likely pathogenic, or hypomorphic class 5 with intermediate effects. The study collects saliva samples from family members to test for these variants and applies statistical models to evaluate the likelihood that a variant causes disease. Genetic analyses are performed by partner laboratories, and results contribute to refining variant classification and recommendations. During the study, participants provide saliva samples for genetic testing and consent to share their data anonymously for analysis. Researchers monitor co-segregation of variants with disease in families over up to 15 years. The main outcome is the classification of selected variants based on family data, which may impact genetic counseling and clinical management. Results are shared at the group level without revealing individual test outcomes.
Actively Recruiting
Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.
1-10 of 39
1